From The Washington Post: In 2017, numerous politicians, advocacy groups, and other stakeholders began to raise questions about the rising costs of prescription drugs. Under attack, the pharmaceutical industry attempted to blame pharmacy benefit managers, for-profit companies that negotiate drug price discounts on behalf of employers and insurers, which has led to major intra-industry conflict.
MIA relies on the support of its readers to exist. Please consider a donation to help us provide news, essays, podcasts and continuing education courses that explore alternatives to the current paradigm of psychiatric care. Your tax-deductible donation will help build a community devoted to creating such change.